AstraZeneca Diabetes Drug Combination Shows Promise in StudyBy
Bydureon and Forxiga reduced weight, blood pressure in trial
Combination may be additional option before insulin treatment
AstraZeneca Plc said a combination of two diabetes medications significantly lowered blood sugar, weight and blood pressure in a study that will support its use to delay insulin treatment.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.